

Date: 13th July, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to the Company's disclosure dated 7th March 2025 regarding the completion of the USFDA inspection of its Bioequivalence Facility at Vadodara, we wish to inform that the Company has been made aware that the United States Food and Drug Administration ("USFDA") has issued a Warning Letter dated 10th July 2026 to the Clinical Investigator associated with a bioequivalence study conducted at the Company's Bioequivalence Facility. The inspection was conducted by the USFDA during the period from 3rd March 2025 to 7th March 2025.

The Warning Letter pertains to observation regarding Informed Consent Form (ICF) in relation to a bioequivalence study. The observations do not relate to data integrity.

Based on the Company's preliminary assessment, the Warning Letter does not impose any restriction on the operations of the Company's Bioequivalence Facility. The Company is coordinating with the Clinical Investigator for submission of an appropriate response to the USFDA within the stipulated timeline.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith as Annexure-I.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

G Krishnan
Chief Financial Officer
Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

1	Name of the Authority	United States Food and Drug Administration (USFDA).
2	Nature and details of the action(s) taken or order(s) passed	The Company has been informed that the USFDA has issued a Warning Letter dated 10 th July 2026 to the Clinical Investigator associated with a bioequivalence study conducted at the Company's Bioequivalence Facility.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	The Company became aware of the Warning Letter on 12 th July, 2026.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The Warning Letter pertains to observation regarding Informed Consent Form (ICF) in relation to a bioequivalence study. The observations do not relate to data integrity.
5	Impact on financial, operational or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Based on the Company's preliminary assessment, no material financial impact has been identified at this stage. The Company is evaluating the matter and is coordinating with the Clinical Investigator in relation to the response to the USFDA.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
 Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123